title: Possible therapeutic effect of lipid supplementation on neurological complications in liver transplant recipients.
abstract: Neurological complications (NCs) represent a serious problem following liver transplantation and may develop either because of various peri-operative factors or the toxicity of immunosuppression. Although the causality assessment of NCs can be particularly difficult in the setting of organ transplantation, calcineurin inhibitors (CNIs) might influence NCs to a certain extent, regardless of the etiology. Therefore, minimizing the influence of CNIs could be a reasonable strategy for alleviating NCs. Based on our hypothesis that lipid supplementation prevents lipophilic CNIs from crossing the blood-brain barrier, soybean oil was administered to five liver transplant patients with NCs. In all of these patients, the neurological symptoms improved without discontinuing or reducing the dose of CNIs. Thus, lipid supplementation might be able to reduce the adverse neurological effects of CNIs.
authors: Division of Frontier Medical Science, Department of Surgery, Programs for Biomedical Research, Graduate School of Biomedical Science, Hiroshima University, 1-2-3 Kasumi, Minami-Ku, Hiroshima, Japan.
authors: Kentaro
authors: K
authors: Ide
authors: Hideki
authors: H
authors: Ohdan
authors: Hiroyuki
authors: H
authors: Tahara
authors: Kohei
authors: K
authors: Ishiyama
authors: Masayuki
authors: M
authors: Shishida
authors: Toshimitsu
authors: T
authors: Irei
authors: Masahiro
authors: M
authors: Ohira
authors: Hirotaka
authors: H
authors: Tashiro
authors: Toshiyuki
authors: T
authors: Itamoto
authors: Toshimasa
authors: T
authors: Asahara
mesh_terms: D000328:Adult; D000368:Aged; D001812:Blood-Brain Barrier; D065095:Calcineurin Inhibitors; D016572:Cyclosporine / Q000009:adverse effects / Q000037:antagonists & inhibitors / Q000378:metabolism / Q000627:therapeutic use; D005260:Female; D006801:Humans; D007166:Immunosuppressive Agents / Q000009:adverse effects* / Q000037:antagonists & inhibitors* / Q000378:metabolism / Q000627:therapeutic use; D016031:Liver Transplantation; D008297:Male; D008875:Middle Aged; D009422:Nervous System Diseases / Q000139:chemically induced* / Q000517:prevention & control*; D013024:Soybean Oil / Q000627:therapeutic use*; D016559:Tacrolimus / Q000009:adverse effects / Q000037:antagonists & inhibitors / Q000378:metabolism / Q000627:therapeutic use
chemical_list: D065095:Calcineurin Inhibitors; D007166:Immunosuppressive Agents; D013024:Soybean Oil; D016572:Cyclosporine; D016559:Tacrolimus